Stock Forecast

  InVivo Therapeutics Holdings Corp. ( NVIV) Stock. Should you Buy or Sell?    $ 5.92

0.41 (6.48 %)

InVivo Therapeutics Holdings Corp. Analysis

Updated on 10-09-2022
Symbol NVIV
Price $5.92
Beta 1.306
Volume Avg. $731.9 thousand
Market Cap $8.24 M
52 Week Range $3.5 - $17.75

InVivo Therapeutics Holdings Corp. opened the day at $5.92 which is +'6.48 % on yesterday's close. InVivo Therapeutics Holdings Corp. has a 52 week high of $17.75 and 52 week low of $3.5, which is a difference of $14.25. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $8.24 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy InVivo Therapeutics Holdings Corp. for $8.24 M, it would take 15 years to get your money back. InVivo Therapeutics Holdings Corp. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


InVivo Therapeutics Holdings Corp. Stock Forecast - Is InVivo Therapeutics Holdings Corp. a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreSell
DE ScoreNeutral
PE ScoreSell
PB ScoreNeutral
Overall RecommendationNeutral

Growth and Value

PE Ratio -0.462
Dividend Yiel 0.000
Net Profit Margin 0.000

Valuing InVivo Therapeutics Holdings Corp.

Price Book Value Ratio 0.639 Price To Book Ratio 0.639
Price To Sales Ratio 0.000 Price Earnings Ratio -0.462

How liquid is InVivo Therapeutics Holdings Corp.

Current Ratio 5.641
Quick Ratio 5.413


Debt Ratio 0.203 Debt Equity Ratio 0.254
Long Term Debt To Capitalization 0.056 Total Debt To Capitalization 0.081

Latest news about InVivo Therapeutics Holdings Corp.

7 Biotech Stocks to Buy That Have Millionaire-Maker Potential

This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.

Date : 10/09/2021

InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has enrolled 15 patients with acute spinal cord injury into the INSPIRE 2.0 Study, or 75% of the total 20-patient enrollment target for the study. The INSPIRE 2.0 study is a randomized, controlled trial (20-patient, 10 subjects in each study arm), that is designed

Date : 08/09/2021

3 Biotech Penny Stocks That You Need to Know About In 2021

Are these the best biotech penny stocks to watch in 2021? The post 3 Biotech Penny Stocks That You Need to Know About In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information |

Date : 20/07/2021

Best Penny Stocks To Watch For July 2021

Penny Stocks For Your Watch List In July The post Best Penny Stocks To Watch For July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information |

Date : 14/07/2021

NVIV Stock Increases Over 36% Intraday: Why It Happened

The stock price of Invivo Therapeutics Holdings Corp (NASDAQ: NVIV) increased by over 36% during intraday trading. This is why it happened.

Date : 13/07/2021

About InVivo Therapeutics Holdings Corp.

CEO : Dr. Richard Toselli
Sector : Healthcare
Industry : Biotechnology

Website :

Exchange : NASDAQ Capital Market

Description :

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

My Newsletter

Sign Up For Updates & Newsletters